Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Revumenib: a new therapy for AML patients

Cancer Currents: An NCI Cancer Research Blog - NCI

National Cancer Institute (NCI) on LinkedIn: A new type of

Therapeutic implications of menin inhibition in acute leukemias

National Cancer Institute (NCI) on LinkedIn: A new type of

Danielle Murphy, FNP-BC on LinkedIn: I am thrilled to announce I

Revumenib Shows Promise in Acute Leukemia - CancerConnect

Juan Manuel Pérez Huacuja Urista posted on LinkedIn

Namrata Gautam on LinkedIn: Signals released from dying cancer

Diane Reedy on LinkedIn: Drug Shortages Near an All-Time High

Hayarpi Javrushyan on LinkedIn: Revumenib Shows Promise for